DB:PMR

Stock Analysis Report

Executive Summary

Pharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally.

Snowflake

Fundamentals

Reasonable growth potential and slightly overvalued.

Share Price & News

How has Pharma Mar's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.1%

PMR

1.0%

DE Biotechs

1.4%

DE Market


1 Year Return

82.0%

PMR

1.3%

DE Biotechs

3.8%

DE Market

Return vs Industry: PMR exceeded the German Biotechs industry which returned 1.3% over the past year.

Return vs Market: PMR exceeded the German Market which returned 3.8% over the past year.


Shareholder returns

PMRIndustryMarket
7 Day-0.1%1.0%1.4%
30 Day3.2%-4.7%1.3%
90 Day5.5%-4.6%3.1%
1 Year82.0%82.0%1.5%1.3%7.0%3.8%
3 Year-30.2%-30.2%67.3%65.6%18.5%8.3%
5 Yearn/a12.9%10.4%42.2%22.9%

Price Volatility Vs. Market

How volatile is Pharma Mar's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Pharma Mar undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PMR (€1.92) is trading below our estimate of fair value (€18.29)

Significantly Below Fair Value: PMR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PMR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PMR is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PMR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PMR is overvalued based on its PB Ratio (19.8x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Pharma Mar forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

80.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PMR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: PMR is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: PMR's loss is forecast to worsen by 0% next year.

Revenue vs Market: PMR's revenue is expected to decline over the next 3 years (-5.7% per year).

High Growth Revenue: PMR's revenue is forecast to decline over the next 3 years (-5.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PMR's Return on Equity is forecast to be very high in 3 years time (62.2%).


Next Steps

Past Performance

How has Pharma Mar performed over the past 5 years?

-40.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PMR is unprofitable, and losses have increased over the past 5 years at a rate of -40.8% per year.

Accelerating Growth: Unable to compare PMR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PMR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: PMR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: PMR is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PMR is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Pharma Mar's financial position?


Financial Position Analysis

Short Term Liabilities: PMR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PMR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PMR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PMR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: PMR's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if PMR's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: PMR has a high level of physical assets or inventory.

Debt Coverage by Assets: PMR has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Next Steps

Dividend

What is Pharma Mar's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate PMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PMR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PMR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PMR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PMR's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Pharma Mar's salary, the management and board of directors tenure and is there insider trading?

11.5yrs

Average management tenure


CEO

José María Fernández Sousa-Faro 0

0yrs

Tenure

€294,000

Compensation

Mr. José María Fernández Sousa-Faro, Ph.D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000. Mr. Fernández Sousa-Faro serves as the Chief Executive Officer and President of Pharma Mar ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether José María's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: José María's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

11.5yrs

Average Tenure

Experienced Management: PMR's management team is seasoned and experienced (11.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buy€58,02301 Jul 19
María Blanca Hernández Rodríguez
EntityIndividual
Shares32,235
Max Price€1.80

Ownership Breakdown


Management Team

  • Juan Carlos-Torres Carretero (70yo)

    • Tenure: 0yrs
  • Pedro Fernández Puentes

    Executive Vice-Chairman

    • Tenure: 0yrs
    • Compensation: €124.00k
  • José María Fernández Sousa-Faro

    Founder

    • Tenure: 0yrs
    • Compensation: €294.00k
  • Pascal Besman

    Chief Operating Officer

    • Tenure: 2.9yrs
  • Luis Mora Capitán

    Managing Director of Oncology Business Unit

    • Tenure: 12.5yrs
  • Luis Rupérez

    Director of Human Resources & Information Technologies

    • Tenure: 16.3yrs
  • Elena Calleja Crespo

    Director of Finance & Administration

    • Tenure: 11.5yrs
  • Juan Nogués

    Director of Marketing and Sales

    • Tenure: 6.7yrs
  • María Luisa de Francia Caballero

    Chief Financial Officer

    • Tenure: 19.8yrs
  • José Luis Moreno Martinez-Losa

    Director of Investor Relations & Capital Markets

    • Tenure: 4.8yrs

Board Members

  • Pedro Fernández Puentes

    Executive Vice-Chairman

    • Tenure: 0yrs
    • Compensation: €124.00k
  • José María Fernández Sousa-Faro

    Founder

    • Tenure: 0yrs
    • Compensation: €294.00k
  • Eduardo Serra Rexach (73yo)

    Independent Director

    • Tenure: 0yrs
    • Compensation: €35.00k
  • José Félix Pérez-Orive Carceller

    Director

    • Tenure: 0yrs
  • M. Carlos Solchaga Catalán (75yo)

    Independent Director

    • Tenure: 0yrs
    • Compensation: €35.00k
  • Ana Palacio del Vallelersundi

    Independent Director

    • Tenure: 0yrs
    • Compensation: €77.00k
  • Montserrat Andrade Detrell

    Proprietary Director

    • Tenure: 0yrs
    • Compensation: €34.00k
  • José Leyte Verdejo

    Director

    • Tenure: 0yrs
  • Carlos Pazos Campos

    Independent Director

    • Tenure: 0.8yrs
  • Valentín de Torres-Solanot del Pino (57yo)

    Independent Director

    • Tenure: 1.8yrs

Company Information

Pharma Mar, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pharma Mar, S.A.
  • Ticker: PMR
  • Exchange: DB
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €424.104m
  • Shares outstanding: 221.23m
  • Website: https://www.pharmamar.com

Number of Employees


Location

  • Pharma Mar, S.A.
  • Avenida de los Reyes, 1
  • Pol. Industrial La Mina – Norte
  • Madrid
  • Madrid
  • 28770
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHMBME (Bolsas y Mercados Espanoles)YesBearer SharesESEURNov 2015
PHMEBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEURNov 2015
PMRDB (Deutsche Boerse AG)YesBearer SharesDEEURNov 2015
0RC6LSE (London Stock Exchange)YesBearer SharesGBEURNov 2015
PHMM.FOTCPK (Pink Sheets LLC)YesBearer SharesUSUSDNov 2015
PHM1 NBMV (Bolsa Mexicana de Valores)YesBearer SharesMXMXNNov 2015

Biography

Pharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. The company operates through two segments, Biopharma ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 21:41
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.